http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17925364

Outgoing Links

Predicate Object
contentType Clinical Trial|Clinical Trial, Phase II|Journal Article
endingPage 260
issn 1573-0646
0167-6997
issueIdentifier 3
pageRange 255-260
publicationName Investigational New Drugs
startingPage 255
bibliographicCitation Vogelzang NJ, Aklilu M, Stadler WM, Dumas MC, Mikulski SM. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs. 2001;19(3):255–60. doi: 10.1023/a:1010633004157. PMID: 11561684.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8a058f88ce52d67ced98757d70380b7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_69388755a67c53e351f23795ced90c59
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b52e34f9349a5bc7fb9f45e5cc5153a2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_25563a60ba51c60b61d7cc3ea31e194c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f44d27e9ff85825512b47f09140678b9
date 200108
identifier https://pubmed.ncbi.nlm.nih.gov/11561684
https://doi.org/10.1023/a:1010633004157
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372
https://portal.issn.org/resource/ISSN/1573-0646
https://portal.issn.org/resource/ISSN/0167-6997
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/
title A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer
discusses http://id.nlm.nih.gov/mesh/M0001483
http://id.nlm.nih.gov/mesh/M0163607
http://id.nlm.nih.gov/mesh/M0019070
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7170
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8237
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8482

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID347909856

Total number of triples: 34.